The current U.S. presidential administration has issued executive orders that address the pricing of pharmaceuticals in the United States and proposed a so-called most favored nation pricing policy, which would tie the price of drugs in the United States to the lowest price in a group of other countries. While it is unclear whether and how these executive orders and proposals will be implemented, the policies are likely to have a negative impact on the pharmaceutical industry.
